Market Overview

UPDATE: Canaccord Genuity Raises HeartWare International's PT

Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking
Heartware International (HTWR) Q2 2015 Results - Earnings Call Webcast (Seeking Alpha)

According to a research report published this morning, Canaccord Genuity has increased HeartWare International's (NASDAQ: HTWR) PT from $95 to $101.

In the report, Canaccord Genuity commented, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September."

Canaccord Genuity maintains its Buy rating on HeartWare International, which closed yesterday at $77.14.

Latest Ratings for HTWR

Jul 2015JP MorganMaintainsOverweight
May 2015JP MorganMaintainsOverweight
May 2015BarclaysMaintainsOverweight

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (HTWR)

Get Benzinga's Newsletters